Univariate analyses of clinical features with CNS relapse among single-route prophylaxis recipients
| Characteristic . | Overall (n = 1130) . | CNS relapse (n = 64) . | No CNS relapse (n = 1066) . | OR . | 95% CI . | P . |
|---|---|---|---|---|---|---|
| Male sex, n (%) | 666 (58.4) | 39 (5.9) | 627 (94.1) | 1.09 | 0.65-1.83 | .78 |
| Median age, y (range) | 62 (16-86) | 61 (21-83) | 62 (18-86) | — | — | 0.33 |
| < 70, n (%) | 852 (75.3) | 54 (6.3) | 798 (93.7) | — | — | Ref |
| ≥ 70, n (%) | 278 (24.6) | 10 (3.6) | 268 (96.4) | 0.55 | 0.28-1.10 | .1 |
| ECOG PS 0-1, n (%) | 844 (74.7) | 42 (5.0) | 802 (95.0) | 0.70 | 0.37-1.30 | .25 |
| Baseline renal impairment, n (%) | 172 (15.2) | 9 (5.2) | 163 (94.8) | 0.90 | 0.43-1.87 | .78 |
| B symptoms, n (%) | 415 (36.7) | 27 (6.5) | 388 (93.5) | 1.30 | 0.77-2.18 | .76 |
| Serum LDH, n (%) | ||||||
| Not elevated | 339 (30.0) | 8 (12.5) | 331 (31.1) | — | — | Ref |
| Elevated, <3× ULN | 598 (53.0) | 42 (65.6) | 556 (52.2) | 3.13 | 1.45-6.74 | .002 |
| Elevated, ≥3× ULN | 147 (13.0) | 12 (18.8) | 135 (12.7) | 3.68 | 1.47-9.20 | .003 |
| Missing/unknown | 46 (4.0) | 2 (5.7) | 44 (4.1) | 1.92 | 0.40-9.36 | .43 |
| Stage, n (%) | ||||||
| Limited (I-II) | 227 (20.1) | 13 (5.7) | 214 (94.3) | — | — | Ref |
| Advanced (III-IV) | 903 (79.9) | 51 (5.6) | 852 (94.4) | 0.99 | 0.53-1.85 | .96 |
| Number EN sites, n (%) | ||||||
| 0 | 190 (16.8) | 5 (2.6) | 185 (97.4) | — | — | Ref |
| 1 | 523 (46.3) | 27 (5.2) | 496 (94.8) | 2.01 | 0.76-5.31 | .15 |
| ≥2 | 417 (36.9) | 32 (7.8) | 385 (92.2) | 3.08 | 1.18-8.02 | .02 |
| EN site(s) involved, n (%) | ||||||
| Renal/adrenal | 133 (11.8) | 8 (6.0) | 125 (94.0) | 1.08 | 0.50-2.31 | .85 |
| Testis | 69 (6.1) | 8 (11.6) | 61 (88.4) | 2.36 | 1.08-5.16 | .03 |
| Breast | 34 (3.0) | 4 (11.8) | 30 (88.2) | 2.30 | 0.79-6.75 | .13 |
| Sinus | 82 (7.3) | 2 (2.4) | 80 (97.4) | 0.40 | 0.10-1.66 | .19 |
| Bone marrow | 124 (11.0) | 11 (8.9) | 113 (91.1) | 1.75 | 0.89-3.45 | .1 |
| CNS-IPI score, n (%) | ||||||
| 0-1 (low) | 196 (18.4) | 10 (5.1) | 186 (94.9) | — | — | Ref |
| 2-3 (moderate) | 546 (51.4) | 21 (3.8) | 525 (96.2) | 0.74 | 0.34-1.61 | .055 |
| ≥4 (high) | 321 (30.2) | 27 (8.4) | 294 (91.6) | 1.71 | 0.81-3.61 | .02 |
| Histology, n (%) | ||||||
| DLBCL | 750 (67.0) | 41 (5.5) | 709 (94.5) | — | — | Ref |
| HGBL | 305 (27.2) | 20 (6.6) | 285 (93.4) | 1.21 | 0.69-2.09 | .49 |
| Cell of origin (DLBCL only), n (%) | ||||||
| Germinal center (GCB) | 340 (45.3) | 11 (3.2) | 329 (96.8) | — | — | Ref |
| Non-GCB | 316 (42.1) | 21 (6.6) | 295 (93.4) | 2.13 | 1.01-4.49 | .047 |
| Double-hit status, n (%) | ||||||
| DH evaluable | 875 (77.4) | 52 (5.9) | 823 (94.1) | — | — | Ref |
| Confirmed DH/TH* | 243 (27.7) | 15 (6.2) | 228 (93.8) | 1.06 | 0.57-1.97 | .86 |
| Frontline chemotherapy regimen, n (%) | ||||||
| R-CHOP | 536 (47.5) | 31 (5.8) | 505 (94.2) | — | — | Ref |
| R-EPOCH (+/− dose adjustment) | 509 (45.1) | 27 (5.3) | 482 (94.7) | 1.25 | 0.51-3.10 | .74 |
| Other | 85 (7.4) | 6 (7.1) | 79 (92.9) | 0.91 | 0.54-1.55 | .64 |
| CNS prophylaxis route, n (%) | ||||||
| Intrathecal | 894 (79.1) | 48 (5.4) | 846 (94.6) | — | — | Ref |
| Intravenous (HD-MTX) | 236 (20.9) | 16 (6.8) | 220 (93.2) | 1.28 | 0.71-2.30 | .4 |
| Characteristic . | Overall (n = 1130) . | CNS relapse (n = 64) . | No CNS relapse (n = 1066) . | OR . | 95% CI . | P . |
|---|---|---|---|---|---|---|
| Male sex, n (%) | 666 (58.4) | 39 (5.9) | 627 (94.1) | 1.09 | 0.65-1.83 | .78 |
| Median age, y (range) | 62 (16-86) | 61 (21-83) | 62 (18-86) | — | — | 0.33 |
| < 70, n (%) | 852 (75.3) | 54 (6.3) | 798 (93.7) | — | — | Ref |
| ≥ 70, n (%) | 278 (24.6) | 10 (3.6) | 268 (96.4) | 0.55 | 0.28-1.10 | .1 |
| ECOG PS 0-1, n (%) | 844 (74.7) | 42 (5.0) | 802 (95.0) | 0.70 | 0.37-1.30 | .25 |
| Baseline renal impairment, n (%) | 172 (15.2) | 9 (5.2) | 163 (94.8) | 0.90 | 0.43-1.87 | .78 |
| B symptoms, n (%) | 415 (36.7) | 27 (6.5) | 388 (93.5) | 1.30 | 0.77-2.18 | .76 |
| Serum LDH, n (%) | ||||||
| Not elevated | 339 (30.0) | 8 (12.5) | 331 (31.1) | — | — | Ref |
| Elevated, <3× ULN | 598 (53.0) | 42 (65.6) | 556 (52.2) | 3.13 | 1.45-6.74 | .002 |
| Elevated, ≥3× ULN | 147 (13.0) | 12 (18.8) | 135 (12.7) | 3.68 | 1.47-9.20 | .003 |
| Missing/unknown | 46 (4.0) | 2 (5.7) | 44 (4.1) | 1.92 | 0.40-9.36 | .43 |
| Stage, n (%) | ||||||
| Limited (I-II) | 227 (20.1) | 13 (5.7) | 214 (94.3) | — | — | Ref |
| Advanced (III-IV) | 903 (79.9) | 51 (5.6) | 852 (94.4) | 0.99 | 0.53-1.85 | .96 |
| Number EN sites, n (%) | ||||||
| 0 | 190 (16.8) | 5 (2.6) | 185 (97.4) | — | — | Ref |
| 1 | 523 (46.3) | 27 (5.2) | 496 (94.8) | 2.01 | 0.76-5.31 | .15 |
| ≥2 | 417 (36.9) | 32 (7.8) | 385 (92.2) | 3.08 | 1.18-8.02 | .02 |
| EN site(s) involved, n (%) | ||||||
| Renal/adrenal | 133 (11.8) | 8 (6.0) | 125 (94.0) | 1.08 | 0.50-2.31 | .85 |
| Testis | 69 (6.1) | 8 (11.6) | 61 (88.4) | 2.36 | 1.08-5.16 | .03 |
| Breast | 34 (3.0) | 4 (11.8) | 30 (88.2) | 2.30 | 0.79-6.75 | .13 |
| Sinus | 82 (7.3) | 2 (2.4) | 80 (97.4) | 0.40 | 0.10-1.66 | .19 |
| Bone marrow | 124 (11.0) | 11 (8.9) | 113 (91.1) | 1.75 | 0.89-3.45 | .1 |
| CNS-IPI score, n (%) | ||||||
| 0-1 (low) | 196 (18.4) | 10 (5.1) | 186 (94.9) | — | — | Ref |
| 2-3 (moderate) | 546 (51.4) | 21 (3.8) | 525 (96.2) | 0.74 | 0.34-1.61 | .055 |
| ≥4 (high) | 321 (30.2) | 27 (8.4) | 294 (91.6) | 1.71 | 0.81-3.61 | .02 |
| Histology, n (%) | ||||||
| DLBCL | 750 (67.0) | 41 (5.5) | 709 (94.5) | — | — | Ref |
| HGBL | 305 (27.2) | 20 (6.6) | 285 (93.4) | 1.21 | 0.69-2.09 | .49 |
| Cell of origin (DLBCL only), n (%) | ||||||
| Germinal center (GCB) | 340 (45.3) | 11 (3.2) | 329 (96.8) | — | — | Ref |
| Non-GCB | 316 (42.1) | 21 (6.6) | 295 (93.4) | 2.13 | 1.01-4.49 | .047 |
| Double-hit status, n (%) | ||||||
| DH evaluable | 875 (77.4) | 52 (5.9) | 823 (94.1) | — | — | Ref |
| Confirmed DH/TH* | 243 (27.7) | 15 (6.2) | 228 (93.8) | 1.06 | 0.57-1.97 | .86 |
| Frontline chemotherapy regimen, n (%) | ||||||
| R-CHOP | 536 (47.5) | 31 (5.8) | 505 (94.2) | — | — | Ref |
| R-EPOCH (+/− dose adjustment) | 509 (45.1) | 27 (5.3) | 482 (94.7) | 1.25 | 0.51-3.10 | .74 |
| Other | 85 (7.4) | 6 (7.1) | 79 (92.9) | 0.91 | 0.54-1.55 | .64 |
| CNS prophylaxis route, n (%) | ||||||
| Intrathecal | 894 (79.1) | 48 (5.4) | 846 (94.6) | — | — | Ref |
| Intravenous (HD-MTX) | 236 (20.9) | 16 (6.8) | 220 (93.2) | 1.28 | 0.71-2.30 | .4 |
All listed P values are 2-sided.
CI, confidence interval; CNS, central nervous system; DH, double-hit; DLBCL, diffuse large B-cell lymphoma; EN, extranodal; FL, follicular lymphoma; GCB, germinal center subtype (Hans criteria); HGBL, high grade B-cell lymphoma; iNHL, indolent non-Hodgkin lymphoma; IPI, international prognostic index; LDH, lactate dehydrogenase; OR, odds ratio; PS, performance status; TH, triple hit; ULN, upper limit of normal.
Percentage of DH evaluable patients. Percentages are otherwise referenced within each row.